Nitrogen Attached Indirectly To The Six-membered Hetero Ring By Nonionic Bonding Patents (Class 514/357)
-
Patent number: 8481571Abstract: A method of treating coronavirus infection. The method includes administering to a subject suffering from or being at risk of suffering from such infection an effective amount of a compound of formula (I). Each variable in this formula is defined in the specification.Type: GrantFiled: May 3, 2005Date of Patent: July 9, 2013Assignee: Academia SinicaInventors: Chi-Huey Wong, Chung-Yi Wu, Jia-Tsrong Jan
-
Patent number: 8481456Abstract: Active compound combinations are disclosed which comprise (A) a dithiino-tetracarboximide of formula (I) and a further insecticidally active compound (B). Methods for controlling animal pests such as insects and/or unwanted acarids and for curatively or preventively controlling the phytopathogenic fungi of plants or crops are also disclosed as well as the use of a composition according to the invention for the treatment of seed, to a method for protecting a seed and to the treated seed.Type: GrantFiled: November 17, 2010Date of Patent: July 9, 2013Assignee: Bayer CropScience AGInventors: Thomas Seitz, Ulrike Wachendorff-Neumann, Heike Hungenberg, Peter Dahmen
-
Publication number: 20130172393Abstract: Phenoxyalkyl pyridinium oxime compounds for use in treating organophosphate poisoning.Type: ApplicationFiled: May 12, 2011Publication date: July 4, 2013Inventors: Janice E. Chambers, Howard W. Chambers, Edward C. Meek
-
Patent number: 8476305Abstract: A novel therapeutic agent or prophylactic agent for an inflammatory bowel disease is provided. An amino alcohol derivative represented by the general formula (1): which is a sphingosine-1-phosphate receptor agonist or a pharmaceutically acceptable salt or hydrate thereof are a therapeutic agent or prophylactic agent for an inflammatory bowel disease comprises.Type: GrantFiled: February 6, 2009Date of Patent: July 2, 2013Assignee: Kyorin Pharmaceutical Co., Ltd.Inventors: Naoya Yamamuro, Koichi Nakamaru, Tokutarou Yasue
-
Patent number: 8476306Abstract: The invention relates to novel inhibitors of urokinase and to their preparation and use for the therapy, prophylaxis and diagnosis of a tumor, in particular for reducing the formation of tumor metastases.Type: GrantFiled: November 22, 2010Date of Patent: July 2, 2013Assignee: The Medicines Company (Leipzig) GmbHInventors: Joerg Stuerzebecher, Torsten Steinmetzer, Andrea Schweinitz
-
Publication number: 20130165460Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: ApplicationFiled: February 20, 2013Publication date: June 27, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130158034Abstract: Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.Type: ApplicationFiled: June 21, 2012Publication date: June 20, 2013Applicant: Amgen Inc.Inventors: James BROWN, Jian J. CHEN, Vijay Keshav GORE, Scott HARRIED, Daniel B. Horne, Matthew R. KALLER, Qingyian LIU, Holger MONENSCHEIN, Thomas T. NGUYEN, Nobuko NISHIMURA, Wenge ZHONG
-
Publication number: 20130156865Abstract: Certain PDE-4 inhibitors are useful for the treatment of myeloid and linphoyd malignancies.Type: ApplicationFiled: December 14, 2012Publication date: June 20, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Patent number: 8466180Abstract: Novel compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to methods of using them to combat and control insect, acarine, mollusc and nematode pests.Type: GrantFiled: September 7, 2007Date of Patent: June 18, 2013Assignee: Syngenta Crop Protection LLCInventors: Pierre Joseph Marcel Jung, Stephan Trah, Christopher Richard Ayles Godfrey, William Lutz, Peter Maienfisch, Werner Zambach
-
Publication number: 20130150321Abstract: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about 88 parts.Type: ApplicationFiled: February 6, 2013Publication date: June 13, 2013Applicant: MCNEIL-PPC, INC.Inventor: McNeil-PPC, Inc.
-
Publication number: 20130150386Abstract: Described herein are methods for the treatment of lung cancer in a subject. In particular, methods are provided for the treatment of resistant lung cancer with a combination of entinostat and an EGFR inhibitor.Type: ApplicationFiled: December 7, 2012Publication date: June 13, 2013Applicant: SYNDAX PHARMACEUTICALS, INC.Inventor: Syndax Pharmaceuticals, Inc.
-
Patent number: 8461189Abstract: The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: GrantFiled: June 24, 2008Date of Patent: June 11, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Richard W. Heidebrecht, Jr., Thomas A. Miller, Matthew G. Stanton, David J. Witter
-
Publication number: 20130143861Abstract: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to less than about 24, 5, 3 or 1 hour(s), and the maximum AF episode duration may be reduced to less than about 20, 10 or 5 hours. According to some methods of the invention, the reduced stroke rate upon administration of budiodarone and AC is less than the age-adjusted overall stroke rate. Further, some methods provide that patients who were refractory to one or more anti-arrhythmic drugs prior to administration of budiodarone may also be treated. Some methods provide for prevention of atrial remodeling and others provide for the reversal of atrial remodeling, including methods to quantify the reversal of atrial remodeling.Type: ApplicationFiled: February 4, 2013Publication date: June 6, 2013Applicant: ARMETHEON, INC.Inventor: Armetheon, Inc.
-
Patent number: 8455480Abstract: The present invention relates to novel active substance combinations which contain firstly at least one known compound of the formula (I) in which R1 and A have the meanings given in the description, and secondly at least one further known active substance from the class of the neonicotinoids, and which are highly suitable for controlling animal pests such as insects and undesired acarids.Type: GrantFiled: September 13, 2008Date of Patent: June 4, 2013Assignee: Bayer Cropscience AGInventors: Heike Hungenberg, Peter Jeschke, Robert Velten, Wolfgang Thielert
-
Publication number: 20130136794Abstract: Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer.Type: ApplicationFiled: April 21, 2011Publication date: May 30, 2013Applicant: PEKING UNIVERSITYInventors: Runtao Li, Zemei Ge, Jingrong Cui, Xingyl Sun, Zhongqing Wang, Xu Yan
-
Publication number: 20130137648Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.Type: ApplicationFiled: January 23, 2013Publication date: May 30, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130137682Abstract: A pest control composition comprising a hydrazide compound shown by formula (1) below (in the formula, G, M, Q1, Q2, Q3, Q4, R2, R4, R5, R6 and m have the same meanings described in the specification) and a neonicotinoid compound selected from the group consisting of imidacloprid, thiacloprid, acetamiprid, nitenpyram, clothianidin, and thiamethoxam, and a method for controlling pests whereby an effective dose of the hydrazide compound represented by formula (1) and a neonicotinoid compound selected from the group consisting of imidacloprid, thiacloprid, acetamiprid, nitenpyram, clothianidin, and thiamethoxam is applied to a pest or a pest habitat.Type: ApplicationFiled: July 25, 2011Publication date: May 30, 2013Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventor: Kaori Ikari
-
Publication number: 20130137690Abstract: The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: ApplicationFiled: January 28, 2013Publication date: May 30, 2013Inventors: Paul Harrington, Richard W. Heidebrecht, JR., Solomon Kattar, Thomas A. Miller, Karin M. Otte, Phieng Siliphaivanh, Matthew G. Stanton, Paul Tempest, Kevin J. Wilson, David J. Witter
-
Publication number: 20130137731Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treatingh depression by administering the ethanamine compound.Type: ApplicationFiled: January 24, 2013Publication date: May 30, 2013Applicant: AstraZeneca ABInventor: AstraZeneca AB
-
Patent number: 8450349Abstract: Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants.Type: GrantFiled: September 11, 2008Date of Patent: May 28, 2013Assignee: E5 Pharma LLCInventors: Robert J. Edwards, Jr., Chih-Ting Huang, Nam-Mew Pui
-
Publication number: 20130130898Abstract: The present invention relates to compositions of fungicidally active compounds comprising at least one active compound I selected from 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (3?,4?,5?-trifluoro-biphenyl-2-yl)-amide (fluxapyroxade), bixafen, fluopyram, isopyrazam, sedaxane, penflufen and penthiopyrad and at least one further active component II as defined below.Type: ApplicationFiled: August 2, 2011Publication date: May 23, 2013Inventors: Markus Gewehr, Jochen Dietz, Egon Haden
-
Publication number: 20130131085Abstract: The present invention features compounds of formula I or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of CYP enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by CYP enzymes.Type: ApplicationFiled: December 13, 2012Publication date: May 23, 2013Applicant: ABBOTT LABORATORIESInventors: Larry L. Klein, Hui-Ju Chen, Ming C. Yeung, Charles A. Flentge, John T. Randolph, Peggy P. Huang, Douglas K. Hutchinson, Dale J. Kempf
-
Patent number: 8445689Abstract: Compounds having the following generic formula are disclosed.Type: GrantFiled: April 11, 2012Date of Patent: May 21, 2013Assignee: Dow AgroSciences, LLC.Inventors: Nneka T. Breaux, Michael R. Loso, Timothy C. Johnson, Jonathan M. Babcock, Benjamin M. Nugent, Timothy P. Martin, Annette Vitale Brown, Ronald Ross, Jr., William C. Lo, Matthias S. Ober
-
Publication number: 20130123225Abstract: Disclosure is provided for carbamate compounds that prevent, remove and/or inhibit the formation of biofilms, compositions including these compounds, devices including these compounds, and methods of using the same.Type: ApplicationFiled: January 4, 2013Publication date: May 16, 2013Inventor: North Carolina State University
-
Publication number: 20130123307Abstract: N-Substituted sulfoximines are effective at controlling insects resistant to common insecticides.Type: ApplicationFiled: December 18, 2012Publication date: May 16, 2013Applicant: Dow AgroSciences LLCInventor: Dow AgroSciences LLC
-
Patent number: 8440659Abstract: The present invention is a composition comprising a neonicotinoid-based compound having a high degree of insecticide activity, an organic solvent and a surfactant. The present invention is also a method that allows the obtaining of lumber that does not require termite-proofing treatment following production of lumber by injecting this composition into a tree trunk and allowing the chemical to circulate and disperse within the tree trunk.Type: GrantFiled: March 10, 2005Date of Patent: May 14, 2013Assignee: LANXESS Deutschland GmbHInventors: Kunitoshi Watanabe, Toshio Suzuki, Suguru Shinya
-
Patent number: 8440666Abstract: Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.Type: GrantFiled: October 30, 2008Date of Patent: May 14, 2013Assignee: Nissan Chemical Industries, Ltd.Inventors: Yukihiro Shigeta, Yutaka Hirokawa, Hiroshi Nagai, Kei Nagae, Tsuneo Watanabe, Megumi Io, Yusuke Shintani, Junji Kamon, Masato Horikawa, Kazuya Takeuchi
-
Publication number: 20130116203Abstract: The present invention provides glucosinolate and isothiocyanate compounds and related methods for synthesizing these compounds and analogs. In certain embodiments, these glucosinolate and isothiocyanate compounds are useful and chemopreventive and or chemotherapeutic agents.Type: ApplicationFiled: November 7, 2011Publication date: May 9, 2013Inventors: Scott R. Rajski, Jared Rae Mays
-
Publication number: 20130116215Abstract: The invention features novel pharmaceutical combinations useful for the treatment of neurological diseases, specifically neurodegenerative diseases. The novel pharmaceutical combinations of the invention demonstrate additive or synergistic effect in silico and in vivo. The invention also relates to methods of treatment of neurological and neurodegenerative diseases including the pharmaceutical combinations of the invention.Type: ApplicationFiled: October 25, 2012Publication date: May 9, 2013Inventors: Mireia Coma, Patrick Aloy, Albert Pujol, Xavier Gomis, Baldomero Oliva, Alberto Lleó, José Manuel Mas
-
Patent number: 8435968Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).Type: GrantFiled: September 18, 2009Date of Patent: May 7, 2013Assignee: PIMCO 2664 LimitedInventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
-
Publication number: 20130109674Abstract: The present invention relates to, among other things, methods for treating trigeminal cephalgias such as migraine and migraine like headaches and other cerebrovascular conditions associated with pain and or inflammation. When non-steroidal anti inflammatory drugs (NSAIDs), such as ketoprofen, are applied locally using specific topical formulations immediate relief of pain is obtained. Intense pain is typically reduced to mild pain or no pain within 30 minutes of application of the topical formulation. The NSAID may be given in combination with other pharmacological agents, such as vasoconstrictors, opioids, decongestants and/or non-opioid migraine drugs, such as triptans and ergots and agents that affect serotonin receptors as agonists, antagonists or partial agonists.Type: ApplicationFiled: December 17, 2010Publication date: May 2, 2013Applicant: Achelios Therapeutics LLCInventors: Harry J. Leighton, Matthew J. Buderer, Crist J. Frangakis
-
Patent number: 8431599Abstract: Compounds of Formulas 1 and 2 where the variables have the meaning disclosed in the specification, have analgesic and in some cases immunostimulant activity.Type: GrantFiled: September 12, 2012Date of Patent: April 30, 2013Assignees: Allergan, Inc., ExonHit Therapeutics SAInventors: Bertrand Leblond, Eric Beausoleil, Thierry Taverne, John E. Donello
-
Publication number: 20130102556Abstract: Combination methods for treatment of cancer and of blood disorders, using PG-11047 ((2Z)-N1,N4-bis[3-(ethy-lammo) propyl]-2-butene-1,4-diamine) and PG-11048 ((2E)-N1,N4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine) in combination with DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, or both DNA methyltransferase inhibitors and histone deacetylase inhibitors, are disclosed. Hematopoietic cancers, lung cancers, mesothelioma, cutaneous T-cell lymphoma (CTCL), multiple myeloma, solid tumors, and blood disorders such as myelodysplastic syndromes can be treated using the methods of the invention.Type: ApplicationFiled: February 2, 2011Publication date: April 25, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Laurence Marton, Robert A. Casero
-
Publication number: 20130102642Abstract: Synergistic pesticidal mixtures are provided.Type: ApplicationFiled: November 27, 2012Publication date: April 25, 2013Applicant: DOW AGROSCIENCES LLCInventor: DOW AGROSCIENCES LLC
-
Publication number: 20130101687Abstract: Insecticidal compositions have at least one active agent and at least one insecticide. The active agent can include perilla oil, a component found in perilla oil, or a perillaldehyde or carvone analog. The insecticide can include a pyrethrum, pyrethrin, pyrethroid, neonicotinoid, chlofenapyr, ethiprole, sulfoxoflor, carbamate, organophosphate, or organochlorine. Methods for controlling insects include contacting an insect with an effective amount of a composition described in this specification. Modified plants that produce an active agent can be contacted with an insecticide.Type: ApplicationFiled: July 13, 2012Publication date: April 25, 2013Inventors: Michael Dean Willis, Marie Elizabeth Saunders, Darryl Ramoutar, Joanna Maria Szymczyk, Frances Nita Krenick, Andrea Rohrbacher
-
Publication number: 20130102609Abstract: The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin.Type: ApplicationFiled: December 14, 2012Publication date: April 25, 2013Applicant: LIGAND PHARMACEUTICALS INC.Inventor: Ligand Pharmaceuticals Inc.
-
Patent number: 8426433Abstract: This invention relates to new chemical compounds, application of these compounds as anticoagulants, pharmaceutical compositions, and plasma-substituting solutions on their basis, and can be used for treating thromboembolic complications of diseases such as myocardial infarction, stroke, and thrombosis of deep veins or a pulmonary artery; and for preventing hypercoagulation conditions in consequence of injuries, surgeries, sepsis, various obstetric pathologies, in disaster medicine, resuscitation, and so on.Type: GrantFiled: June 27, 2008Date of Patent: April 23, 2013Assignee: Obschestvo S Ogranichennoi Otvetsttvennoctiyu “Bionika”Inventors: Elena Ivanovna Sinauridze, Fazoil Inoyatovich Ataullakhanov, Andrey Alexandrovich Butylin, Vladimir Borisovich Sulimov, Alexey Nickolayevich Romanov, Alexey Alexeevich Bogolyubov, Yury Vladimirovich Kuznetsov, Irina Vladimirovna Gribkova, Alexander Sergeevich Gorbatenko, Olga Anatolievna Kondakova
-
Publication number: 20130096138Abstract: Disclosed are novel thiourea or urea derivatives inhibitory of HIV activity. Also provided are a method for preparing the thiourea or urea derivatives, and a pharmaceutical composition for the prophylaxis or therapy of AIDS comprising the derivatives. Having high inhibitory activity against HIV, the thiourea or urea derivatives can be effectively used in the prophylaxis or therapy of AIDS.Type: ApplicationFiled: June 17, 2011Publication date: April 18, 2013Applicant: AVIXGEN INC.Inventors: Ji Chang You, Gyoon Hee Han, Chul Ho Lee, Doo Na Song, Koo Hwan Chung
-
Publication number: 20130096164Abstract: The present invention relates to the use, as active ingredient, of a 1-N-(halo-3-pyridylmethyl)-N-methylamino-1-alkylamino-2-nitroethylene derivative for preparing a veterinary pharmaceutical composition for topical application in the treatment of external parasites, in particular fleas, in domestic animals, in particular in dogs and cats, intended to be applied at least every 2 weeks.Type: ApplicationFiled: November 30, 2012Publication date: April 18, 2013Applicant: VIRBACInventor: VIRBAC
-
Publication number: 20130096105Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.Type: ApplicationFiled: November 30, 2012Publication date: April 18, 2013Applicant: NOVARTIS AGInventor: NOVARTIS AG
-
Publication number: 20130090359Abstract: A method for treating a TRPV1-mediated disease by administering to a patient a therapeutically effective amount of a compound or a salt thereof having the following formula [I]: wherein A represents a lower alkylene group or a lower alkenylene group; R1 represents a hydrogen atom, an unsubstituted or substituted alkyl group or an unsubstituted or substituted alkenyl group; and R2 and R3 are the same or different and represent a hydrogen atom, an unsubstituted lower alkyl group or a lower alkyl group substituted by a monocyclic cycloalkyl group, a polycyclic cycloalkyl group or an aryl group.Type: ApplicationFiled: November 19, 2012Publication date: April 11, 2013Applicant: Santen Pharmaceutical Co., Ltd.Inventor: Santen Pharmaceutical Co., Ltd.
-
Publication number: 20130084340Abstract: The present invention includes compositions and methods for the controlled release of active agents in a shelf-stable liquid formulation by blending one or more controlled release microbeads comprising one or more active agents, preparing a dense, thixotropic solution having a density that is at, or about, the density of the one or more microbeads comprising a thixotropic agent, water and one or more preservatives under conditions that reduce bubble formation and mixing the microbeads and the thixotropic solutions in a mixer that lacks scraping paddles.Type: ApplicationFiled: November 26, 2012Publication date: April 4, 2013Applicant: NEOS THERAPEUTICS, LPInventors: Mark Tengler, Paul Taskey, Daniel Lockhart, Russell McMahen
-
Patent number: 8410020Abstract: A composition comprising at least a pyridylethylbenzamide derivative of general formula (I) (a) and a compound capable of inhibiting the methionine biosynthesis (b) in a (a)/(b) weight ratio of from 0.01 to 20. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the phytopathogenic fungi of crops by using this composition.Type: GrantFiled: February 10, 2005Date of Patent: April 2, 2013Assignee: Bayer Cropscience AGInventors: Jean-Marie Gouot, Marie-Claire Grosjean-Cournoyer
-
Patent number: 8409595Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.Type: GrantFiled: September 29, 2009Date of Patent: April 2, 2013Assignee: Medicis Pharmaceutical CorporationInventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
-
Publication number: 20130079373Abstract: The invention relates to substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.Type: ApplicationFiled: September 25, 2012Publication date: March 28, 2013Inventor: Gruenenthal GmbH
-
Publication number: 20130079376Abstract: Compounds are provided according to formula I: where R, R?, R3, R4, R5, and R6 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, Alzheimer' s Disease, Down's syndrome, Parkinson's Disease, and others.Type: ApplicationFiled: July 6, 2012Publication date: March 28, 2013Inventors: Bijan Almassian, Martin J. Sadowski, Xu Kevin Lin
-
Publication number: 20130079313Abstract: The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.Type: ApplicationFiled: September 26, 2012Publication date: March 28, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130079377Abstract: The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.Type: ApplicationFiled: September 25, 2012Publication date: March 28, 2013Applicant: Gruenenthal GmbHInventor: Gruenenthal GmbH
-
Publication number: 20130071476Abstract: Rapid melt tablets that dissolve and release an active component in the oral cavity are comprised of a pharmaceutical active ingredient such as dextromethorphan complexed with a resin that is effective in taste-masking the otherwise bitter taste of the active making it convenient for oral administration. The drug/resin-complexed particles can be coated with water swellable or water insoluble polymers to impart controlled release properties to the active ingredient. A rapid melt tablet also comprises diluents, sweeteners, flavors, disintegrants and other excipients to form granules that can be compressed into tablets at low pressure without the need for a binding agent.Type: ApplicationFiled: August 31, 2012Publication date: March 21, 2013Inventor: Subraman Rao Cherukuri
-
Patent number: 8399494Abstract: The present invention is directed to 2,5-disubstituted phenyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 26, 2009Date of Patent: March 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Jeffrey M. Bergman, Paul J. Coleman, Anthony J. Roecker, John D. Schreier